F-1/A: Evaxion Biotech A/S Announces Proposed Public Offering to Advance AI-Immunology Platform

Evaxion Biotech A/S plans a public offering of ADSs and warrants to fund its preclinical and clinical pipeline and support ongoing operations.

Summary

• Evaxion Biotech A/S is planning a public offering involving American Depositary Shares (ADSs) and warrants.
• The offering includes up to 2,032,520 ADSs, pre-funded warrants for the same number of ADSs, and warrants to purchase an additional 2,032,520 ADSs.
• The assumed public offering price is $7.38 per ADS and accompanying warrant, based on the closing price on January 26, 2024.
• The warrants will have an exercise price of $ per share and are exercisable for five years.
• The company intends to use the net proceeds to advance its preclinical and clinical pipeline and for working capital.
• H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering, which is expected to terminate on March 1, 2024.
• Evaxion's strategy focuses on its AI-Immunology platform, targeting value realization through targets, pipeline, and responders, with a multi-partner approach.
• The company's cash and cash equivalents were $7.7 million as of January 29, 2024.

Sentiment

Score: 6

Explanation: The document presents a balanced view, highlighting both the potential of Evaxion's technology and the risks associated with its business. The sentiment is neutral, reflecting the inherent uncertainties in the biotechnology industry.

Positives

• The offering will provide capital to advance Evaxion's preclinical and clinical pipeline.
• The AI-Immunology platform is clinically validated and adaptable, offering a strong value proposition for partnerships.
• The company has a refined strategy focused on value realization and execution.
• The participation of MSD Global Health Innovation Fund in a recent private placement supports the potential of the AI-Immunology platform.

Negatives

• The company has incurred significant losses since its inception and expects to continue to do so.
• The offering is being conducted on a best efforts basis, and there is no guarantee that the company will raise the desired amount.
• The company is subject to reduced public company reporting requirements as a foreign private issuer and emerging growth company.

Risks

• The company is a clinical-stage company with only two product candidates in early clinical trials.
• The company will require substantial additional financing to achieve its goals, which may not be available.
• Pharmaceutical product development is inherently uncertain, and there is no guarantee that any of the product candidates will receive marketing approval.
• The company's business model is based upon partnering, and there is no guarantee that it will be able to secure needed partnerships.
• The company faces significant competition in an environment of rapid technological and scientific change.
• The company relies on third parties in the conduct of significant aspects of its preclinical studies and clinical trials.
• The company may not be in compliance with the EIB Loans beneficial ownership requirements following this offering.

Future Outlook

The company anticipates several important milestones in 2024, including advancing its AI-Immunology platform and progressing its clinical and preclinical pipeline.

Management Comments

• Christian Kanstrup, CEO, highlights the potential of the AI-Immunology platform to revolutionize oncology.
• Management believes the predictive power of the AI models will reduce drug development timelines, costs, and attrition.

Industry Context

The document highlights the competitive landscape in the pharmaceutical market, particularly in immuno-oncology and infectious diseases, where Evaxion faces competition from major pharmaceutical companies and specialized biotechnology firms.

Comparison to Industry Standards

• The document compares the overall response rate of EVX-01 in combination with anti-PD-1 treatment (67%) to the historical overall response rate of anti-PD-1 treatment alone (40%).
• The document compares the complete response rate of EVX-01 in combination with anti-PD-1 treatment (17%) to the historical complete response rate of anti-PD-1 treatment alone (7%).
• The document compares the performance of AI-DeeP to classical biomarkers (TMB & PD-L1) in predicting patient response to immunotherapy.
• The document compares the performance of PIONEER to state-of-the-art public tools for neoantigen prediction.
• The document compares the performance of EDEN to reverse vaccinology (RV) in identifying bacterial vaccine antigens.

Legal Proceedings

• The document mentions a legal proceeding initiated by Statens Serum Institut (SSI) regarding the ownership of a patent application related to EVX-01.

Stakeholder Impact

• Shareholders: Potential dilution from the offering, but also potential for increased value if the company successfully executes its strategy.
• Employees: Continued employment and potential for career growth as the company advances its pipeline.
• Patients: Potential for new and improved treatment options for cancer and infectious diseases.
• Partners: Opportunities for collaboration and value creation through the AI-Immunology platform.

Next Steps

• Advance preclinical and clinical pipeline.
• Generate business development income.
• Pursue partnerships based on the AI-Immunology platform.
• Continue clinical trial activities for EVX-01.

Key Dates

Keywords

ADSs, warrants, offering, Evaxion, pipeline, clinical, AI, Immunology, preclinical, biotech